 | • レポートコード：MRC2-11QY04007 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は非黒色腫皮膚がんのグローバル市場について調査・分析したレポートです。種類別（化学療法、放射線療法、光線力学療法）市場規模、用途別（病院、診療所、外来外科センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別非黒色腫皮膚がんの競争状況、市場シェア ・世界の非黒色腫皮膚がん市場：種類別市場規模 2015年-2020年（化学療法、放射線療法、光線力学療法） ・世界の非黒色腫皮膚がん市場：種類別市場規模予測 2021年-2026年（化学療法、放射線療法、光線力学療法） ・世界の非黒色腫皮膚がん市場：用途別市場規模 2015年-2020年（病院、診療所、外来外科センター、その他） ・世界の非黒色腫皮膚がん市場：用途別市場規模予測 2021年-2026年（病院、診療所、外来外科センター、その他） ・北米の非黒色腫皮膚がん市場分析：米国、カナダ ・ヨーロッパの非黒色腫皮膚がん市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの非黒色腫皮膚がん市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の非黒色腫皮膚がん市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの非黒色腫皮膚がん市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Boehringer Ingelheim、Bristol-Myers Squibb、Eli Lilly、Roche、Merck、Novartis、Mylan、Sun Pharmaceutical、Almirall、Elekta、Varian Medical Systems、Sensus Healthcare、iCAD、Accuray、Ion Beam Applications ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts.
Radiation therapy has a market share approaching 88% in the non-melanoma skin cancer treatment market in 2017 itself and is unlikely to cede this commanding position anytime soon.
Market Analysis and Insights: Global Non-Melanoma Skin Cancer Market
The global Non-Melanoma Skin Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Non-Melanoma Skin Cancer Scope and Market Size
Non-Melanoma Skin Cancer market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Non-Melanoma Skin Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Roche
Merck
Novartis
Mylan
Sun Pharmaceutical
Almirall
Elekta
Varian Medical Systems
Sensus Healthcare
iCAD
Accuray
Ion Beam Applications
Market segment by Type, the product can be split into
Chemotherapy
Radiation Therapy
Photodynamic Therapy
Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-Melanoma Skin Cancer Revenue
1.4 Market by Type
1.4.1 Global Non-Melanoma Skin Cancer Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Radiation Therapy
1.4.4 Photodynamic Therapy
1.5 Market by Application
1.5.1 Global Non-Melanoma Skin Cancer Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Non-Melanoma Skin Cancer Market Perspective (2015-2026)
2.2 Global Non-Melanoma Skin Cancer Growth Trends by Regions
2.2.1 Non-Melanoma Skin Cancer Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-Melanoma Skin Cancer Historic Market Share by Regions (2015-2020)
2.2.3 Non-Melanoma Skin Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non-Melanoma Skin Cancer Market Growth Strategy
2.3.6 Primary Interviews with Key Non-Melanoma Skin Cancer Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Non-Melanoma Skin Cancer Players by Market Size
3.1.1 Global Top Non-Melanoma Skin Cancer Players by Revenue (2015-2020)
3.1.2 Global Non-Melanoma Skin Cancer Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-Melanoma Skin Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-Melanoma Skin Cancer Market Concentration Ratio
3.2.1 Global Non-Melanoma Skin Cancer Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-Melanoma Skin Cancer Revenue in 2019
3.3 Non-Melanoma Skin Cancer Key Players Head office and Area Served
3.4 Key Players Non-Melanoma Skin Cancer Product Solution and Service
3.5 Date of Enter into Non-Melanoma Skin Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Non-Melanoma Skin Cancer Historic Market Size by Type (2015-2020)
4.2 Global Non-Melanoma Skin Cancer Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Non-Melanoma Skin Cancer Market Size by Application (2015-2020)
5.2 Global Non-Melanoma Skin Cancer Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Non-Melanoma Skin Cancer Market Size (2015-2020)
6.2 Non-Melanoma Skin Cancer Key Players in North America (2019-2020)
6.3 North America Non-Melanoma Skin Cancer Market Size by Type (2015-2020)
6.4 North America Non-Melanoma Skin Cancer Market Size by Application (2015-2020)
7 Europe
7.1 Europe Non-Melanoma Skin Cancer Market Size (2015-2020)
7.2 Non-Melanoma Skin Cancer Key Players in Europe (2019-2020)
7.3 Europe Non-Melanoma Skin Cancer Market Size by Type (2015-2020)
7.4 Europe Non-Melanoma Skin Cancer Market Size by Application (2015-2020)
8 China
8.1 China Non-Melanoma Skin Cancer Market Size (2015-2020)
8.2 Non-Melanoma Skin Cancer Key Players in China (2019-2020)
8.3 China Non-Melanoma Skin Cancer Market Size by Type (2015-2020)
8.4 China Non-Melanoma Skin Cancer Market Size by Application (2015-2020)
9 Japan
9.1 Japan Non-Melanoma Skin Cancer Market Size (2015-2020)
9.2 Non-Melanoma Skin Cancer Key Players in Japan (2019-2020)
9.3 Japan Non-Melanoma Skin Cancer Market Size by Type (2015-2020)
9.4 Japan Non-Melanoma Skin Cancer Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Non-Melanoma Skin Cancer Market Size (2015-2020)
10.2 Non-Melanoma Skin Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-Melanoma Skin Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia Non-Melanoma Skin Cancer Market Size by Application (2015-2020)
11 India
11.1 India Non-Melanoma Skin Cancer Market Size (2015-2020)
11.2 Non-Melanoma Skin Cancer Key Players in India (2019-2020)
11.3 India Non-Melanoma Skin Cancer Market Size by Type (2015-2020)
11.4 India Non-Melanoma Skin Cancer Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Non-Melanoma Skin Cancer Market Size (2015-2020)
12.2 Non-Melanoma Skin Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-Melanoma Skin Cancer Market Size by Type (2015-2020)
12.4 Central & South America Non-Melanoma Skin Cancer Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Boehringer Ingelheim
13.1.1 Boehringer Ingelheim Company Details
13.1.2 Boehringer Ingelheim Business Overview
13.1.3 Boehringer Ingelheim Non-Melanoma Skin Cancer Introduction
13.1.4 Boehringer Ingelheim Revenue in Non-Melanoma Skin Cancer Business (2015-2020))
13.1.5 Boehringer Ingelheim Recent Development
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Details
13.2.2 Bristol-Myers Squibb Business Overview
13.2.3 Bristol-Myers Squibb Non-Melanoma Skin Cancer Introduction
13.2.4 Bristol-Myers Squibb Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
13.2.5 Bristol-Myers Squibb Recent Development
13.3 Eli Lilly
13.3.1 Eli Lilly Company Details
13.3.2 Eli Lilly Business Overview
13.3.3 Eli Lilly Non-Melanoma Skin Cancer Introduction
13.3.4 Eli Lilly Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
13.3.5 Eli Lilly Recent Development
13.4 Roche
13.4.1 Roche Company Details
13.4.2 Roche Business Overview
13.4.3 Roche Non-Melanoma Skin Cancer Introduction
13.4.4 Roche Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
13.4.5 Roche Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview
13.5.3 Merck Non-Melanoma Skin Cancer Introduction
13.5.4 Merck Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
13.5.5 Merck Recent Development
13.6 Novartis
13.6.1 Novartis Company Details
13.6.2 Novartis Business Overview
13.6.3 Novartis Non-Melanoma Skin Cancer Introduction
13.6.4 Novartis Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
13.6.5 Novartis Recent Development
13.7 Mylan
13.7.1 Mylan Company Details
13.7.2 Mylan Business Overview
13.7.3 Mylan Non-Melanoma Skin Cancer Introduction
13.7.4 Mylan Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
13.7.5 Mylan Recent Development
13.8 Sun Pharmaceutical
13.8.1 Sun Pharmaceutical Company Details
13.8.2 Sun Pharmaceutical Business Overview
13.8.3 Sun Pharmaceutical Non-Melanoma Skin Cancer Introduction
13.8.4 Sun Pharmaceutical Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
13.8.5 Sun Pharmaceutical Recent Development
13.9 Almirall
13.9.1 Almirall Company Details
13.9.2 Almirall Business Overview
13.9.3 Almirall Non-Melanoma Skin Cancer Introduction
13.9.4 Almirall Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
13.9.5 Almirall Recent Development
13.10 Elekta
13.10.1 Elekta Company Details
13.10.2 Elekta Business Overview
13.10.3 Elekta Non-Melanoma Skin Cancer Introduction
13.10.4 Elekta Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
13.10.5 Elekta Recent Development
13.11 Varian Medical Systems
10.11.1 Varian Medical Systems Company Details
10.11.2 Varian Medical Systems Business Overview
10.11.3 Varian Medical Systems Non-Melanoma Skin Cancer Introduction
10.11.4 Varian Medical Systems Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
10.11.5 Varian Medical Systems Recent Development
13.12 Sensus Healthcare
10.12.1 Sensus Healthcare Company Details
10.12.2 Sensus Healthcare Business Overview
10.12.3 Sensus Healthcare Non-Melanoma Skin Cancer Introduction
10.12.4 Sensus Healthcare Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
10.12.5 Sensus Healthcare Recent Development
13.13 iCAD
10.13.1 iCAD Company Details
10.13.2 iCAD Business Overview
10.13.3 iCAD Non-Melanoma Skin Cancer Introduction
10.13.4 iCAD Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
10.13.5 iCAD Recent Development
13.14 Accuray
10.14.1 Accuray Company Details
10.14.2 Accuray Business Overview
10.14.3 Accuray Non-Melanoma Skin Cancer Introduction
10.14.4 Accuray Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
10.14.5 Accuray Recent Development
13.15 Ion Beam Applications
10.15.1 Ion Beam Applications Company Details
10.15.2 Ion Beam Applications Business Overview
10.15.3 Ion Beam Applications Non-Melanoma Skin Cancer Introduction
10.15.4 Ion Beam Applications Revenue in Non-Melanoma Skin Cancer Business (2015-2020)
10.15.5 Ion Beam Applications Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Non-Melanoma Skin Cancer Key Market Segments
Table 2. Key Players Covered: Ranking by Non-Melanoma Skin Cancer Revenue
Table 3. Ranking of Global Top Non-Melanoma Skin Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Non-Melanoma Skin Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Radiation Therapy
Table 7. Key Players of Photodynamic Therapy
Table 8. Global Non-Melanoma Skin Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Non-Melanoma Skin Cancer Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Non-Melanoma Skin Cancer Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Non-Melanoma Skin Cancer Market Share by Regions (2015-2020)
Table 12. Global Non-Melanoma Skin Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Non-Melanoma Skin Cancer Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Non-Melanoma Skin Cancer Market Growth Strategy
Table 18. Main Points Interviewed from Key Non-Melanoma Skin Cancer Players
Table 19. Global Non-Melanoma Skin Cancer Revenue by Players (2015-2020) (Million US$)
Table 20. Global Non-Melanoma Skin Cancer Market Share by Players (2015-2020)
Table 21. Global Top Non-Melanoma Skin Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Melanoma Skin Cancer as of 2019)
Table 22. Global Non-Melanoma Skin Cancer by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Non-Melanoma Skin Cancer Product Solution and Service
Table 25. Date of Enter into Non-Melanoma Skin Cancer Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Non-Melanoma Skin Cancer Market Size by Type (2015-2020) (Million US$)
Table 28. Global Non-Melanoma Skin Cancer Market Size Share by Type (2015-2020)
Table 29. Global Non-Melanoma Skin Cancer Revenue Market Share by Type (2021-2026)
Table 30. Global Non-Melanoma Skin Cancer Market Size Share by Application (2015-2020)
Table 31. Global Non-Melanoma Skin Cancer Market Size by Application (2015-2020) (Million US$)
Table 32. Global Non-Melanoma Skin Cancer Market Size Share by Application (2021-2026)
Table 33. North America Key Players Non-Melanoma Skin Cancer Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Non-Melanoma Skin Cancer Market Share (2019-2020)
Table 35. North America Non-Melanoma Skin Cancer Market Size by Type (2015-2020) (Million US$)
Table 36. North America Non-Melanoma Skin Cancer Market Share by Type (2015-2020)
Table 37. North America Non-Melanoma Skin Cancer Market Size by Application (2015-2020) (Million US$)
Table 38. North America Non-Melanoma Skin Cancer Market Share by Application (2015-2020)
Table 39. Europe Key Players Non-Melanoma Skin Cancer Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Non-Melanoma Skin Cancer Market Share (2019-2020)
Table 41. Europe Non-Melanoma Skin Cancer Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Non-Melanoma Skin Cancer Market Share by Type (2015-2020)
Table 43. Europe Non-Melanoma Skin Cancer Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Non-Melanoma Skin Cancer Market Share by Application (2015-2020)
Table 45. China Key Players Non-Melanoma Skin Cancer Revenue (2019-2020) (Million US$)
Table 46. China Key Players Non-Melanoma Skin Cancer Market Share (2019-2020)
Table 47. China Non-Melanoma Skin Cancer Market Size by Type (2015-2020) (Million US$)
Table 48. China Non-Melanoma Skin Cancer Market Share by Type (2015-2020)
Table 49. China Non-Melanoma Skin Cancer Market Size by Application (2015-2020) (Million US$)
Table 50. China Non-Melanoma Skin Cancer Market Share by Application (2015-2020)
Table 51. Japan Key Players Non-Melanoma Skin Cancer Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Non-Melanoma Skin Cancer Market Share (2019-2020)
Table 53. Japan Non-Melanoma Skin Cancer Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Non-Melanoma Skin Cancer Market Share by Type (2015-2020)
Table 55. Japan Non-Melanoma Skin Cancer Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Non-Melanoma Skin Cancer Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Non-Melanoma Skin Cancer Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Non-Melanoma Skin Cancer Market Share (2019-2020)
Table 59. Southeast Asia Non-Melanoma Skin Cancer Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Non-Melanoma Skin Cancer Market Share by Type (2015-2020)
Table 61. Southeast Asia Non-Melanoma Skin Cancer Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Non-Melanoma Skin Cancer Market Share by Application (2015-2020)
Table 63. India Key Players Non-Melanoma Skin Cancer Revenue (2019-2020) (Million US$)
Table 64. India Key Players Non-Melanoma Skin Cancer Market Share (2019-2020)
Table 65. India Non-Melanoma Skin Cancer Market Size by Type (2015-2020) (Million US$)
Table 66. India Non-Melanoma Skin Cancer Market Share by Type (2015-2020)
Table 67. India Non-Melanoma Skin Cancer Market Size by Application (2015-2020) (Million US$)
Table 68. India Non-Melanoma Skin Cancer Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Non-Melanoma Skin Cancer Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Non-Melanoma Skin Cancer Market Share (2019-2020)
Table 71. Central & South America Non-Melanoma Skin Cancer Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Non-Melanoma Skin Cancer Market Share by Type (2015-2020)
Table 73. Central & South America Non-Melanoma Skin Cancer Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Non-Melanoma Skin Cancer Market Share by Application (2015-2020)
Table 75. Boehringer Ingelheim Company Details
Table 76. Boehringer Ingelheim Business Overview
Table 77. Boehringer Ingelheim Product
Table 78. Boehringer Ingelheim Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 79. Boehringer Ingelheim Recent Development
Table 80. Bristol-Myers Squibb Company Details
Table 81. Bristol-Myers Squibb Business Overview
Table 82. Bristol-Myers Squibb Product
Table 83. Bristol-Myers Squibb Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 84. Bristol-Myers Squibb Recent Development
Table 85. Eli Lilly Company Details
Table 86. Eli Lilly Business Overview
Table 87. Eli Lilly Product
Table 88. Eli Lilly Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 89. Eli Lilly Recent Development
Table 90. Roche Company Details
Table 91. Roche Business Overview
Table 92. Roche Product
Table 93. Roche Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 94. Roche Recent Development
Table 95. Merck Company Details
Table 96. Merck Business Overview
Table 97. Merck Product
Table 98. Merck Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 99. Merck Recent Development
Table 100. Novartis Company Details
Table 101. Novartis Business Overview
Table 102. Novartis Product
Table 103. Novartis Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 104. Novartis Recent Development
Table 105. Mylan Company Details
Table 106. Mylan Business Overview
Table 107. Mylan Product
Table 108. Mylan Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 109. Mylan Recent Development
Table 110. Sun Pharmaceutical Business Overview
Table 111. Sun Pharmaceutical Product
Table 112. Sun Pharmaceutical Company Details
Table 113. Sun Pharmaceutical Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 114. Sun Pharmaceutical Recent Development
Table 115. Almirall Company Details
Table 116. Almirall Business Overview
Table 117. Almirall Product
Table 118. Almirall Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 119. Almirall Recent Development
Table 120. Elekta Company Details
Table 121. Elekta Business Overview
Table 122. Elekta Product
Table 123. Elekta Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 124. Elekta Recent Development
Table 125. Varian Medical Systems Company Details
Table 126. Varian Medical Systems Business Overview
Table 127. Varian Medical Systems Product
Table 128. Varian Medical Systems Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 129. Varian Medical Systems Recent Development
Table 130. Sensus Healthcare Company Details
Table 131. Sensus Healthcare Business Overview
Table 132. Sensus Healthcare Product
Table 133. Sensus Healthcare Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 134. Sensus Healthcare Recent Development
Table 135. iCAD Company Details
Table 136. iCAD Business Overview
Table 137. iCAD Product
Table 138. iCAD Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 139. iCAD Recent Development
Table 140. Accuray Company Details
Table 141. Accuray Business Overview
Table 142. Accuray Product
Table 143. Accuray Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 144. Accuray Recent Development
Table 145. Ion Beam Applications Company Details
Table 146. Ion Beam Applications Business Overview
Table 147. Ion Beam Applications Product
Table 148. Ion Beam Applications Revenue in Non-Melanoma Skin Cancer Business (2015-2020) (Million US$)
Table 149. Ion Beam Applications Recent Development
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Melanoma Skin Cancer Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Radiation Therapy Features
Figure 4. Photodynamic Therapy Features
Figure 5. Global Non-Melanoma Skin Cancer Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Ambulatory Surgical Centers Case Studies
Figure 9. Others Case Studies
Figure 10. Non-Melanoma Skin Cancer Report Years Considered
Figure 11. Global Non-Melanoma Skin Cancer Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Non-Melanoma Skin Cancer Market Share by Regions: 2020 VS 2026
Figure 13. Global Non-Melanoma Skin Cancer Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Non-Melanoma Skin Cancer Market Share by Players in 2019
Figure 16. Global Top Non-Melanoma Skin Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Melanoma Skin Cancer as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Non-Melanoma Skin Cancer Revenue in 2019
Figure 18. North America Non-Melanoma Skin Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Non-Melanoma Skin Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Non-Melanoma Skin Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Non-Melanoma Skin Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Non-Melanoma Skin Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Non-Melanoma Skin Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Non-Melanoma Skin Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
非黒色腫皮膚がん治療の世界市場（～2026年） Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts. Radiation therapy has a market share approaching 88% in the non-melanoma skin cancer treatment market in 2017 itself and is unlike…- 黒色腫がんの世界市場（～2026年） Melanoma Cancer is a skin cancer that develops due to expose of UV rays on the skin. Increasing incidence of melanoma across the globe and rising ozone layer depletion due to global warming are the major factors that are driving the market during the forecast period. Additionally, overexposure to ra…
- 皮膚がん治療薬の世界市場（～2026年） On the basis of the type of tissue affected, there are three major types of skin cancer, namely, basal cell carcinoma, squamous-cell carcinoma, and melanoma. Factors such as increasing incidences of skin cancer, favorable government initiatives, the development of novel immunotherapies, and the exte…
- 皮膚ガンの世界市場（～2026年） Skin cancer is the most common type of cancer, which arise due to uncontrolled growth of abnormal skin cells. It occurs when skin cells are damaged by unrepaired DNA or genetic defects that lead the uncontrolled growth of cells in the skin. Market Analysis and Insights: Global Skin Cancer Market The…
- 皮膚がん診断・治療の世界市場（～2026年） Skin cancer is the uncontrolled development of anomalous skin cells. The major factor that drives the market is that when the sun rays that is the ultra violet rays comes in contact with skin may cause skin cancer. Market Analysis and Insights: Global Skin Cancer Diagnosis and Therapeutics Market Th…